with coenrollment, considering clustering within centers. We examined the effect of coenrollment on safety and the trial outcome. Interventions: None. Measurements and Main Results: Overall, 127 of 548 randomized patients (23.2%) were coenrolled in 25 unique studies. Coenrollment was reported in 17 of 39 centers (43.6%). Patients were most commonly coenrolled in one additional randomized clinical trial (76; 59.8%). Coenrollment was less likely in older patients (odds ratio, 0.87; 95% CI, 0.76-0.997), and in ICUs with greater than 26 beds (odds ratio, 0.56; 95% CI, 0.34-0.94), and more likely by investigators with more than 11 years of experience (odds ratio, 1.73; 95% CI, 1.06-2.82), by research coordinators with more than 8 years of experience (odds ratio, 1.87; 95% CI, 1.11-3.18) and in Canada (odds ratio, 4.66; 95% CI, 1.43-15.15 ). Serious adverse events were similar between coenrolled high-frequency oscillatory ventilation and control patients. Coenrollment did not modify the treatment effect of high-frequency oscillatory ventilation on hospital mortality. Conclusions: Coenrollment occurred in 23% of patients, commonly in younger patients, in smaller centers with more research infrastructure, and in Canada. Coenrollment did not influence patient safety or trial results. (Crit Care Med 2015; 43:328-338) Key Words: acute respiratory distress syndrome; coenrollment; critical illness; mechanical ventilation; randomized trial R ecruitment of eligible patients into critical care trials is challenging due to the severity of acute illness in the ICU, reliance on substitute decision makers for consent, and short time windows for randomization. The enrollment of one patient into more than one study-coenrollment-is an increasingly common approach to increase patient clinical trial participation, yet the practice has not been well studied except in research on HIV (1), resuscitation (2) , thromboprophylaxis in adult critical care (3) , and pediatric critical care (4) . We found no studies of coenrollment in randomized controlled clinical trials (RCTs) of mechanical ventilation.
Coenrollment offers several potential benefits, including reduced competition for similar patients among studies, avoidance of selection bias, increased likelihood of timely completion, and enhanced research cost-effectiveness. Potential disadvantages include patient or substitute decision-maker burden. Unintended interactions may develop (causing harm, or inflated or attenuated treatment effects); furthermore, modified treatment effects may reduce the power of a study unpredictably. Furthermore, bedside staff or research personnel workload may be increased. Although investigators perceive that coenrollment can be ethical and feasible (5) , institutional review boards (IRBs) and protocol prohibitions can hinder such opportunities (6) .
In this study, coenrollment refers to simultaneous or sequential enrollment in two or more studies (5) . Coenrollment in two studies can occur only when a patient fulfills all inclusion criteria and has no exclusion criteria for both studies. This is distinct from factorial design studies, where all patients enrolled are randomized twice, included in both limbs of the factorial trial (7-13).
The overall objective of this study was to describe the characteristics of patients, research personnel and centers involved in coenrollment, studies permitting and precluding coenrollment, and the prevalence, patterns, predictors, and outcomes of coenrollment in OSCILLation for Acute Respiratory Distress Syndrome Treated Early (OSCILLATE), a RCT in patients with acute respiratory distress syndrome (ARDS) (14) . Specific aims were to analyze 1) the proportion of eligible patients previously enrolled in a confounding study that precluded OSCILLATE randomization and the design, affiliation, and funding of these studies; 2) the proportion of OSCILLATE patients coenrolled in at least one other study and the methods (design, consent), affiliation, funding, and timing of coenrollment; 3) the characteristics of patients, research personnel, and centers coenrolling versus not; and 4) the effect of coenrollment on serious adverse events (SAEs) and the primary outcome of OSCILLATE.
METHODS
We analyzed patients with moderate-severe ARDS randomized in an international clinical trial in five countries comparing high-frequency oscillatory ventilation (HFOV) versus low tidal volume and high positive end-expiratory pressure ventilation (control) on hospital mortality (OSCILLation for ARDS Treated Early Trial [ClinicalTrials.gov NCT00474656-pilot; NCT01506401-main trial]).
Nested within OSCILLATE, we conducted an observational study of coenrollment. We used prospectively collected patient and study data on coenrollment (design, funding, and coenrollment timing [i.e., before, concurrent with, or after OSCILLATE enrollment, and each year]). We retrospectively obtained additional data on research infrastructure (personnel and research intensity), center characteristics (hospital and ICU descriptors, research ethics oversight), and coenrolled studies (consenting personnel and requirements, consortia affiliation). Retrospective studies on OSCILLATE patients after trial closure were not considered. We did not prospectively record all research conducted at all sites during OSCILLATE; however, we documented the number of additional studies at each site in 2010 for use in the regression analysis.
The OSCILLATE Steering Committee generally supported coenrollment, in keeping with principles of the Canadian Critical Care Trials Group (CCCTG) (3). The co-principal investigators (N.D.F., M.O.M.) of OSCILLATE discussed the possibility of coenrollment with the principal investigators of other trials and sought input from the OSCILLATE Steering Committee. Once consensus was reached, the other study principal investigators were contacted for further discussion, then the final decision about whether coenrollment was allowed or disallowed was communicated to all OSCILLATE centers. If allowed, centers handled coenrollment according to local policies; thus, some centers allowed coenrollment and others did not, some required case-by-case review, and others initially disallowed but later allowed it. Throughout the trial, SAEs were defined as 1) any event that was fatal or immediately life threatening, permanently disabling, severely incapacitating, or required prolonged inpatient hospitalization, 2) any event that www.ccmjournal.org jeopardized the patient and required medical or surgical intervention to prevent one of the outcomes listed above, and 3) either 1) or 2) was believed, by the attending physician, to be related to OSCILLATE enrollment.
Our framework for coenrollment into two studies is conditional on the patient being eligible for both studies (i.e., the patient fulfills all inclusion criteria and has no exclusion criteria for both studies). Therefore, a patient with elevated intracranial pressure in a trial of decompressive craniectomy versus medical management (15) was not a coenrollment opportunity because elevated intracranial pressure was an exclusion criterion for OSCILLATE. Two examples illustrate our decision making. The first is a coenrollment opportunity-a patient enrolled in a trial of pharmaconutrition (13) who fulfilled all OSCILLATE inclusion and no exclusion criteria and was coenrolled. The second is a patient enrolled in a trial of protocolized sedation with or without daily interruption of benzodiazepine and opioid infusions (16) , who fulfilled all OSCILLATE eligibility criteria. In this scenario, a coenrollment opportunity was disallowed; these patients were not coenrolled in OSCILLATE because routine sedation interruption was considered unsuitable for ARDS patients in either group.
Analysis
Continuous data are summarized as mean (sd) or median (interquartile range, IQR) and categorical data as proportions. We conducted univariable analyses using t test or Wilcoxon rank-sum test for continuous variables and chi-square test or Fisher exact test for categorical variables, comparing characteristics of patients who were coenrolled versus not coenrolled, research coordinators who coenrolled versus those who did not, and centers that coenrolled versus those that did not. We evaluated whether the proportion of patients coenrolled changed over the years of recruitment in Cochran-Armitage trend test. We conducted a multilevel logistic regression to examine factors independently associated with coenrollment, considering clustering of patients and research staff within centers and distinguishing patient from center characteristics. Continuous predictor variables related to investigator (e.g., years of experience), coordinator, or ICU (e.g., number of beds) characteristics were dichotomized at the median value for multivariable analysis. We examined the effect of coenrollment on SAEs and the primary outcome of hospital mortality using chi-square test or Fisher exact test when appropriate. We assessed coenrollment as a modifier of the effect of HFOV on mortality by including an interaction term in logistic regression adjusted for the same covariates (age, baseline acute physiology score, baseline sepsis, and duration of prerandomization hospitalization) (14) .
Ethics
OSCILLATE was approved by all participating centers' IRBs. Written informed consent was obtained from substitute decision makers prior to randomization.
RESULTS
Hospitals were largely teaching institutions (38; 97.4%), with a mean (sd) of 566 (248) hospital beds. Most ICUs were closed (37; 94.9%), with a mean (sd) of 33 (20) 
Aim 1: Confounding Studies That Precluded Coenrollment
We considered all 548 randomized patients and 574 eligible nonrandomized patients in 39 participating centers in five countries. Of 574 eligible nonrandomized patients, the reason for nonenrollment was prior enrollment in a study not permitting coenrollment for 24 patients (4.2%) in 10 studies ( Table 1) .
Aims 2 and 3: Characteristics of Coenrollments
Overall, 127 of 548 randomized patients (23.2%) were coenrolled in 25 unique studies (160 coenrollment events) ( Table 2 ). There is overlap among studies between Tables 1 and 2 because for certain studies, coenrollment was allowed in some but not other OSCILLATE centers, and coenrollment was initially disallowed for some studies but then subsequently allowed (e.g., REDOXS [13] , PROWESS-SHOCK [21] ). Coenrollment was reported in 17 of 39 centers (43.6%) and three of five (60.0%) countries. Among 127 coenrolled patients, the median (IQR) number of additional studies into which one patient was coenrolled was 1 (1, 1) (maximum of 4) ( Table 3) . Of 26 patients coenrolled in two or more additional studies, the commonest combination was one additional RCT and one additional prospective comparative study (nonrandomized comparison) (23.1% of patients) followed by RCT and prospective audit (19.2% of patients). The most common design among the 160 coenrollment events was RCTs (100; 62.5%), observational studies (total 60; prospective comparisons [21; 13.1%], prospective audits [34; 21.5%], qualitative studies [4; 2.5%], and retrospective audits [1; 0.6%]).
Two centers had explicit coenrollment guidelines. Of 160 coenrollment events, 149 (93.1%) required informed consent. Of these, consent was obtained before OSCILLATE (30; 20.1%), concurrent with OSCILLATE (37; 24.8%), or after OSCILLATE enrollment (82; 55.1%). The proportion of patients coenrolled did not increase annually (p = 0.72). In 2010, there were a median of two (1-3) additional observational studies and four (2-6) RCTs concurrently recruiting per site.
Aim 3: Characteristics of Patients, Research Personnel, and Centers
We compare patients, research personnel (research coordinators and site investigators), and centers engaged in coenrollment versus not in Table 4 . In univariable analysis, patients who were coenrolled did not differ from those not coenrolled regarding age, sex, illness severity as measured by Acute Physiology and Chronic Health Evaluation (APACHE) II score, and body mass index. Patients in the HFOV group (63 of 275, 22.9%) were just as likely to be coenrolled as the control group (64 of 273, 23.4%).
There were no differences in numbers or discipline of research personnel or the primary persons obtaining consent in centers coenrolling versus not coenrolling. However, research coordinators who coenrolled had more multicenter trial experience than those who did not (p = 0.02).
Univariable analysis showed that centers coenrolling versus those not coenrolling were of similar size, were just as likely to have participated in the OSCILLATE pilot phase, and were participating concurrently in a similar number of observational studies. However, centers coenrolling were participating in more RCTs than centers not coenrolling (median, 4 [4-6] vs 2.5 [2] [3] [4] [5] ; p = 0.04), and had participated in OSCILLATE for significantly longer (median, 4.8 yr [2.1-5.0 yr] vs 1.9 yr [1.0-2.9 yr]; p = 0.005), and had more experienced research coordinators (median, 11 [10] [11] [12] [13] vs 6 [4] [5] [6] [7] [8] [9] [10] years of experience; p = 0.02).
In multivariable analyses ( 
Aim 4: Effect of Coenrollment on Outcomes
Among patients coenrolled in other studies, rates of SAEs were similar between the HFOV (2 of 63; 3.2%) and control (1 of 64; 1.6%; p = 0.62) groups and similar to the main trial findings (HFOV: 7 of 275 [2.5%] vs control: 1 of 273 [0.4%]; p = 0.07). Also, SAE rates were similar between patients who were coenrolled (3 of 127; 2.4%) versus not coenrolled (5 of 417; 1.2%; p = 0.40).
The primary outcome of OSCILLATE, including coenrolled patients (relative risk of hospital mortality with HFOV, 1.33; 95% CI, 1.09-1.64; p = 0.005), did not change when patients coenrolled in any other studies were excluded (relative risk, 1.26; 95% CI, 1.01-1.58; p = 0.04; n = 421) and when patients coenrolled only in other RCTs were excluded (relative risk, 1.27; 95% CI, 1.02-1.58; p = 0.03; n = 455). ClinicalTrials.gov: NCT01145560. c ClinicalTrials.gov: NCT01285570. There were 24 of 573 eligible patients (4.2%) who were not enrolled in OSCILLation for Acute Respiratory Distress Syndrome Treated Early (OSCILLATE) because they were already enrolled in another randomized controlled trial. Listed in order of frequency of nonenrollment, we listed the study name, intervention (if any), funding, and research affiliation. Studies in which OSCILLATE-eligible patients were enrolled which precluded OSCILLATE enrollment in some participating centers might have been allowed in other centers. Note that coenrollment was initially disallowed by the Methods Center for some studies but was subsequently allowed (e.g., REDOXS, PROWESS-SHOCK). The reasons for nonenrollment in OSCILLATE were variable (coenrollment disallowed by industry study, not pursued due to unique family dynamics, no local experience, etc. 
DISCUSSION
One quarter of patients in this ARDS trial were coenrolled in at least one other study-commonly another RCT. Coenrolled patients within OSCILLATE had a similar illness severity as those who were not coenrolled. We found no differential coenrollment across the two arms of this unblinded trial. Coenrollment did not increase the risk of SAEs. The largest number of coenrollments with any individual RCT was 25 patients (< 5% of patients in OSCILLATE, and smaller percentages in the coenrolled RCTs listed in Table 2 ), making the probability that coenrollment had impacts on the treatment effect in OSCILLATE or other trials unlikely. Indeed, our analysis suggested that coenrollment did not modify the treatment effect of HFOV.
We also found that the absolute number of patients coenrolled was greatest in Canada, reflecting the extensive enrollment of Canadian patients in the trial. However, the proportion of coenrolled patients was highest in the single enrolling center in Saudi Arabia (16 of 44; 36%), followed by Canadian centers (107 of 410; 26%) and the United States (4 of 76; 5%). Given relatively few centers outside Canada, results are nonrepresentative of national practice elsewhere.
Multivariable analysis suggested that younger patients were significantly more likely to be coenrolled than older patients, which may reflect more intensified pursuit of research opportunities for younger patients, or greater concern about coenrollment in the elderly. Smaller ICUs were significantly more likely to coenroll than larger ICUs, perhaps reflecting their research efficiency. Centers with more experienced research coordinators and investigators were more likely to coenroll, suggesting heightened vigilance for, and comfort with, coenrollment.
Our study highlights the lack of a universal approach to coenrollment. Coenrollment decisions permissible by steering committees of each study were subsequently subject to approval at each center, only some of which allowed coenrollment. For other study combinations, coenrollment was originally not considered, and hence did not occur initially with PROWESS-SHOCK (21) or REDOXS (13) . After discussion with relevant stakeholders, it was later allowed for both studies, and either occurred (13) or did not (21) . Regarding another combination, an early coenrollment in Sedation Lightening and Evaluation of A Protocol (16) was an oversight, as this was eventually disallowed. Therefore, coenrollment early in a trial's recruitment, or in centers without an established approach, may occur on a case-by-case basis and evolve. Although no centers had official IRB policies at the time of this study, two centers in Hamilton had IRB-approved coenrollment guidelines and the CCCTG guidelines (31) focused on understanding substitute decision making; index patients were used to screen for substitute decision makers to interview. Note that coenrollment was disallowed for some studies in which patients were coenrolled in error (e.g., Sedation Lightening and Evaluation of A Protocol). (34) comparing tight versus standard glucose control. Of five ICUs participating in both trials, three disallowed coenrollment. The fourth ICU did not record approaches or refusals, but did coenroll one child. In the fifth ICU, of 35 parents approached for both trials, 17 consented to both, 13 consented to one, and five declined both. Consent rates during coenrollment were 29 of 35 (82%) and 18 of 35 (51%) for CATCH and CHiP, respectively, compared with 78% and 51% for a single trial. Coenrollment was interpreted as not jeopardizing recruitment or overwhelming parents (4) .
Coenrollment has been investigated in two adult ICU studies. Burns et al (6) characterized consent encounters and outcomes in a national 1-month prospective observational study in 23 ICUs. Coenrollment was permitted in 19 of 23 ICUs (83%) and occurred in 11 studies on 50 occasions involving 20 of 119 patients (17%). Research staff were unable to obtain consent for 129 patients; in 19 (15%) instances, the trials prohibited coenrollment. In a 67-center thromboprophylaxis trial (PROphylaxis for ThromboEmbolism in Critical Care Trial [PROTECT]) (35) , the proportion of patients coenrolled (19%) (3) was similar to OSCILLATE (23%). Factors associated with coenrollment in PROTECT differed, including illness severity, consent by substitute decision maker (vs patient), greater experience of person obtaining consent, larger center size, and enrollment into the main trial rather than pilot.
Limitations of this report include possible underreporting of patients already in another study who were eligible for OSCILLATE but for whom coenrollment was not pursued. We did not capture surrogates who were not approached for coenrollment or when coenrollment was offered but declined. We did not characterize persons eliciting informed consent or whether there was IRB, industry, or investigator prohibition. Our characterization of research intensity may be affected by recall bias; we acknowledge that shared positions, summer students, and managers may have existed.
Strengths of this study are the focus on patients with ARDS in whom the clinical risks and research risks may theoretically be high. This preplanned longitudinal observational study nested within a randomized trial examined precluding studies, the prevalence, patterns, and outcomes associated with coenrollment. We analyzed predictors using multilevel regression to take into account clustering of patients and research personnel within centers.
Coenrollment is not cited as an item for a clinical trial protocol in the Standard Protocol Items: Recommendations for Interventional Trials checklist (36) or in a clinical trial report in the Consolidated Standards of Reporting Trials checklist (37) . Without empiric evidence that coenrollment increases the risk of bias or affects the generalizability of findings, reporting cannot be considered mandatory. However, enhanced transparency would include the rationale for coenrollment, the approach taken, the proportion of coenrolled patients in each arm and into which other studies, and the consequences, if known, on the results. The impact of coenrollment on interviews of substitute decision makers to explore decisional burden versus appreciation for opportunities would be useful. In one center, consent rates for coenrollment encounters were reportedly similar to single study consent encounters (38) , but further research is warranted. Observational studies or registries in centers with considerable coenrollment experience would illuminate pros and cons and population-specific concerns (39) as well as efficiencies such as modular consent forms (40) .
Guidelines for coenrollment would raise awareness among investigators, IRBs, funders, and regulators. Coenrollment documents may reflect research consortia policies (31, 41) , whereas the U.K. National Institute of Healthcare Research Comprehensive Clinical Research Network produced a guideline encouraging coenrollment in the ICU (32). International coenrollment data remain sparse among countries contributing to global critical care research (42) .
CONCLUSIONS
Coenrollment occurred in one quarter of patients enrolled in this ARDS trial, most commonly in another randomized trial. Coenrollment was more common in younger patients, in smaller centers with more research infrastructure, and in Canada. Coenrollment did not jeopardize patient safety or modify the treatment effect in this international trial. Careful monitoring and reporting of coenrollment is warranted in the ICU setting.
